Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
Executive members of the Liberal Democratic Party’s (LDP) tax panel are considering slightly lowering the current deduction ceiling of a special R&D tax credit system for the next fiscal year. The core component of the system is temporarily capped at…
To read the full story
Related Article
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
- FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- JPMA Tones Down Demand on R&D Tax Credit System, Calls for “Maintenance” Instead of “Perpetuation”
October 20, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…